BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday.

Shares of BlackBerry Limited (NYSE: BB) rose sharply during Tuesday’s session.

The company announced a collaboration with Advanced Micro Devices, Inc. (NASDAQ: AMD), designed to revolutionize next-generation robotic systems by enabling new levels of low latency and jitter, as well as repeatable determinism.

BlackBerry shares jumped 9% to $3.1340 on Tuesday.

Here are some other big stocks recording losses in today’s session.

• Nurix Therapeutics, Inc. (NASDAQ: NRIX) jumped 19% to $16.42. Nurix Therapeutics announced extension of strategic collaboration with Sanofi to develop novel targeted protein degraders of STAT6.
• Taysha Gene Therapies, Inc. (NASDAQ: TSHA) shares climbed 14% to $3.0650 after Piper Sandler initiated coverage on the stock with an Overweight rating and a price target of $9.
• Lyell Immunopharma, Inc. (NASDAQ: LYEL) gained 10.5% to $2.42.
• Wheels Up Experience Inc. (NYSE: UP) climbed 10.3% to $3.00.
• XPeng Inc. (NYSE: XPEV) climbed 8.7% to $8.02.
• Revance Therapeutics, Inc. (NASDAQ: RVNC) gained 8.6% to $4.8350.
• Moderna, Inc. (NASDAQ: MRNA) gained 8.3% to $113.81.
• NIO Inc. (NYSE: NIO) shares rose 7.7% to $4.7050. NIO filed its 2023 annual report on Form 20-F.
• Absci Corporation (NASDAQ: ABSI) gained 7.4% to $6.06.
• Hudbay Minerals Inc. (NYSE: HBM) climbed 7.2% to $8.01 after B of A Securities upgraded the stock from Neutral to Buy.
• Coeur Mining, Inc. (NYSE: CDE) rose 7% to $5.06. Roth MKM analyst Joe Reagor initiated coverage on Coeur Mining with a Buy rating and announced a price target of $5.4.
• Bilibili Inc. (NASDAQ: BILI) gained 5.6% to $11.70.
• Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) gained 5.5% to $8.30.
• Tesla, Inc. (NASDAQ: TSLA) shares rose 2.3% to $176.93. Goldman Sachs analyst Mark Delaney maintained Tesla with a Neutral and lowered the price target from $190 to $175, while Morgan Stanley analyst Adam Jonas maintained the stock with an Overweight and maintained a $310 price target.

Now Read This: Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'